PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

NCT00454779 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: Cisplatin
DRUG: Panitumumab
DRUG: Docetaxel
DRUG: Cisplatin
DRUG: Docetaxel

Sponsor

Amgen